Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Multi-cancer blood test shows real promise in NHS trial

An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also also correctly identified the original site of cancer in 85% of those cases.

Oxford DeLIVER research attracts 1000 patients for innovative Pearl clinical study

1000 patients have been recruited for the Pearl study within the DeLIVER programme.

New tool uses health records to predict risk of developing lung cancer within the next 10 years

A team of researchers from the University of Oxford and the University of Nottingham have developed ‘CanPredict’, a new tool able to identify those most at risk of developing lung cancer over the next 10 years, and put them forward for screening tests earlier, saving time, money and lives.

Prostate cancer AI diagnosis tool begins evaluation in Oxford

Researchers and clinicians in Oxford have begun an evaluation of artificial intelligence (AI) software that could help pathologists diagnose prostate cancer.

Major funding for Oxford will help find new cancer treatments

Cancer Research UK and the National Institute for Health and Care Research are investing over £3 million across the next five years into The University of Oxford’s Experimental Cancer Medicine Centre (ECMC). The investment will enable Oxford to expand its portfolio of precision prevention and early detection cancer trials.

Research confirms important differences in colorectal cancer patients with a history of Inflammatory Bowel Disease

IBD-associated colorectal cancers were found to occur in younger patients and have worse outcomes. Researchers call for urgent improvement of early detection methods to provide more risk-based and personalised care.

Dr Jan Bornschein receives an MRC Clinical Academic Research Partnership (CARP) Award

Dr Bornschein will join the Simmons Group (MRC Human Immunology Unit) for a project developing strategies to identify patients at high risk of gastritis/gastric cancer.

Public talk: Using blood tests to detect cancer

Organised by the NIHR Oxford Biomedical Research Centre, Professor Mark Middleton and patient representative Sue Duncombe discuss how cancer blood tests are being assessed and how they may change how cancer is diagnosed in the NHS.

Dr Brian Nicholson reacts to news that GPs in England will have direct access to book cancer tests for their patients

This initiative, announced by the NHS England Chief Executive, is part of the drive to diagnose cancers earlier in the NHS by “fast-tracking” community-based diagnostic testing.

Assessing a combined approach for risk-stratified population screening for colorectal cancer

Polygenic risk scores only modestly improve the predictive power of the QCancer-10 non-genetic risk score for colorectal cancer

Pancreatic cancer could be diagnosed up to three years earlier

Pancreatic cancer could be identified in patients up to three years earlier than current diagnoses, new research suggests. Weight loss and increasing blood glucose levels are early indicators of pancreatic cancer and could lead to a more timely diagnosis, helping to improve survival rates.

OxCODE researchers at the Early Detection of Cancer Conference 2022

Oxford’s early detection research was featured at this annual event.

Funding boost for Oxford’s early cancer detection research in the NIHR Oxford BRC

The NIHR Oxford Biomedical Research Centre (BRC), a partnership between the University of Oxford and Oxford University Hospitals (OUH) NHS Foundation Trust, will receive £86.6m over the next five years to fund 15 research themes.

Oxford spinout Optellum secures $14m funding to advance pioneering AI-powered lung cancer diagnosis technology

Optellum, a University of Oxford spinout that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a Series A funding round.

Oxford Centre for Early Cancer Detection Symposium 2022 – a recap

On Tuesday 13th September, the Oxford early cancer detection community gathered at Worcester College to discuss the latest developments in this field, sparking ideas and collaborations for future research.

Funding to research metformin’s ability to delay or prevent cancers driven by the mutated TP53 gene

A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin’s mechanism of action when taken as a preventative for mTP53-driven cancers.

Cancer at Oxford

Read about how Oxford's experts are leading the way in cancer prevention, detection and treatment as part of the University's Cancer at Oxford series

Unique clinical imaging dataset released for artificial intelligence research to accelerate diagnosis of prostate cancer

The National Cancer Imaging Translational Accelerator (NCITA) in partnership with the ReIMAGINE Consortium have announced the release of a unique clinical imaging dataset from the Prostate MRI Imaging Study (PROMIS)).

OxCODE travel awards 2022

Congratulations to Joshua Bull, Felix Jackson, Eoghan Mulholland and Lauren Murphy who have been awarded OxCODE funds to attend this year’s Early Detection of Cancer conference in Oregon.

CRUK funding to investigate the molecular drivers of stomach cancer

Dr Francesco Boccellato wins a CRUK Early Detection and Diagnosis primer award to study tissue shape changes in the pre-cancerous stomach conditions, atrophic gastritis and intestinal metaplasia

Load More